Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
50.28
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
2 Stocks to Buy With Less Than $50
↗
July 04, 2025
Via
The Motley Fool
Topics
Intellectual Property
EXELIXIS INC (NASDAQ:EXEL) - An Undervalued Biotech Stock With Strong Fundamentals
↗
July 02, 2025
EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors.
Via
Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential
↗
June 30, 2025
EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup.
Via
Chartmill
3 No-Brainer Stocks to Buy for Under $100 Right Now
↗
June 28, 2025
Via
The Motley Fool
Topics
Intellectual Property
EXELIXIS INC (NASDAQ:EXEL) – A High Growth Momentum Stock with Strong Technical Setup
↗
June 28, 2025
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support...
Via
Chartmill
Analyst Expectations For Exelixis's Future
↗
June 05, 2025
Via
Benzinga
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
↗
June 24, 2025
Via
Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Growth and Momentum Investing
↗
June 24, 2025
EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors.
Via
Chartmill
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
↗
June 23, 2025
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug.
Via
Investor's Business Daily
Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday
↗
June 23, 2025
Via
Benzinga
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
↗
June 23, 2025
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.
Via
Benzinga
AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday
↗
June 23, 2025
Via
Benzinga
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug
↗
June 23, 2025
Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.
Via
Investor's Business Daily
What 9 Analyst Ratings Have To Say About Exelixis
↗
June 23, 2025
Via
Benzinga
These stocks are moving in today's pre-market session
↗
June 23, 2025
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
June 23, 2025
Via
Benzinga
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket
↗
June 23, 2025
Via
Benzinga
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
June 22, 2025
From
Exelixis, Inc.
Via
Business Wire
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
June 20, 2025
From
Exelixis, Inc.
Via
Business Wire
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors
↗
June 17, 2025
EXELIXIS INC (NASDAQ:EXEL) meets key growth investing criteria with strong earnings, revenue growth, and profitability, making it a standout for investors following Louis Navellier's strategy.
Via
Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation
↗
June 13, 2025
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
Via
Chartmill
DoorDash To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday
↗
June 12, 2025
Via
Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Undervalued Biotech Stocks
↗
June 10, 2025
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, growth, and financial health, making it a compelling pick for value investors.
Via
Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup
↗
June 06, 2025
EXELIXIS INC (NASDAQ:EXEL) combines strong earnings momentum with a high technical rating, making it a standout for growth investors. The stock's breakout setup suggests potential upside.
Via
Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential
↗
June 03, 2025
EXELIXIS INC (NASDAQ:EXEL) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities.
Via
Chartmill
2 Top Stocks to Buy With Less Than $100
↗
May 30, 2025
Via
The Motley Fool
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors
↗
May 26, 2025
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.
Via
Chartmill
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
May 22, 2025
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
May 22, 2025
From
Exelixis, Inc.
Via
Business Wire
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation
↗
May 22, 2025
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
